Monoclonal Antibodies: The Foundation of Therapy for Colorectal Cancer in the 21st Century?

Drs. Hoff, Ellis, and Abbruzzese have provided a thorough and useful overview of the current status of the two new monoclonal antibodies, cetuximab (Erbitux) and bevacizumab (Avastin), that have recently become available for the treatment of colorectal cancer.